What is Signal Intelligence?

Beyond Single-Domain Intelligence

Traditional intelligence approaches tend to focus on a single domain — regulatory monitoring, competitive analysis, or market research — operating in isolation. Signal Intelligence breaks down these silos. It recognizes that the most valuable insights emerge at the intersection of domains: a competitor's FDA clearance combined with a recent Series B funding round tells a more complete story than either signal alone.

The CI Platform ingests and correlates signals across four domains simultaneously, building unified company profiles that reveal the full picture of market activity. A clinical trial start in one domain becomes a competitive alert in another; a patent filing connects to a potential partnership opportunity; a funding announcement signals market expansion readiness. This cross-domain intelligence is what separates raw data from genuine strategic advantage.

The Four Domains of Signal Intelligence

Signal intelligence operates across four interconnected domains, each providing a unique window into market activity:

Regulatory Signal Intelligence

The systematic monitoring of global health authorities for new clearances, approvals, certifications, recalls, and regulatory changes. This is the foundational domain — regulatory signals are the most structured, high-confidence indicators of market activity.

Key sources: FDA 510(k) clearances and PMA approvals, EUDAMED NB certificates, ANVISA registrations, NMPA device approvals, PMDA Shonin certificates, Health Canada MDEL licenses, TGA ARTG listings, WHO Prequalification, CDSCO registrations, MFDS certifications.

Competitive Signal Intelligence

Tracking competitor activity through product launches, patent filings, strategic partnerships, market entries, and organizational changes. Competitive signals provide context around who is moving, where they are investing, and what markets they are targeting.

Key sources: USPTO, EPO, WIPO, CNIPA, KIPO, and JPO patent filings; SEC EDGAR disclosures (10-K, 8-K, S-1); press releases and corporate announcements; clinical trial registrations as R&D indicators.

Clinical Signal Intelligence

Monitoring clinical trial activity, investigator networks, study results, and scientific publications. Clinical signals are leading indicators of product development progress — a trial start today signals a regulatory submission tomorrow and a market entry the year after.

Key sources: ClinicalTrials.gov registrations and results, EU CTIS trial authorizations, PubMed biomedical literature, DRKS and other national trial registries, investigator and site activation data.

Market Signal Intelligence

Tracking funding rounds, M&A activity, market expansion announcements, partnership deals, and economic indicators. Market signals reveal financial health, growth trajectory, and strategic direction — the business context that makes regulatory and clinical signals actionable.

Key sources: Crunchbase funding data, Grants.gov SBIR/STTR awards, NIH grant funding, SEC filings for public companies, industry press and news feeds.

How Signals Flow Across Domains

The power of Signal Intelligence lies not in any single domain but in the connections between them. A single company generates signals across all four domains simultaneously, and the CI Platform's entity resolution engine links them into a unified intelligence profile:

Signal Detection

Our crawlers monitor all global public sources around the clock. When an FDA clearance is published, a clinical trial starts enrolling, a patent is granted, or a funding round closes, the signal is ingested within hours.

Cross-Domain Correlation

Each signal is linked to its source company using entity resolution. The same company tracked across FDA filings, patent grants, clinical trials, and funding data builds a unified profile — a single view of that company's complete market activity.

Classification & Scoring

Signals are classified by domain, type, source country, and relevance. Our scoring engine evaluates signal density — a company with regulatory approvals in multiple geographies, active trials, recent patent filings, and fresh funding scores as a higher-priority intelligence target.

Company Enrichment

Each company is enriched with firmographic data: headcount, revenue range, technology focus, regulatory history across all tracked jurisdictions, clinical trial history, patent portfolio, funding history, and key decision-makers.

Intelligence Delivery

Cross-domain intelligence is delivered through customizable alerts, dashboards, and API feeds. Users can monitor competitors across all four domains, generate qualified leads from multi-signal triggers, or receive early warnings of market shifts before they become public knowledge.

24 Data Sources Across Four Domains

The CI Platform ingests data from 24 carefully curated data sources spanning regulatory agencies, patent offices, clinical trial registries, and market databases worldwide:

Regulatory (10 sources)

• FDA (USA) — 510(k) clearances, PMA approvals, recalls
• EUDAMED (EU) — NB certificates, IVDR decisions
• ANVISA (Brazil) — device registrations
• NMPA (China) — device and product registrations
• PMDA (Japan) — medical device approvals
• Health Canada — MDL/MDEL licenses
• MFDS (South Korea) — device certifications
• CDSCO (India) — device registrations
• TGA (Australia) — ARTG listings
• WHO Prequalification — global health products

Patent (6 sources)

• USPTO (USA) — granted patents and applications
• EPO (Europe) — European patent grants
• WIPO (Global) — PCT international applications
• CNIPA (China) — Chinese patent filings
• KIPO (South Korea) — Korean patent filings
• JPO (Japan) — Japanese patent filings

Clinical (4 sources)

• ClinicalTrials.gov — 450K+ registered studies
• EU CTIS — EU clinical trial authorizations
• PubMed — biomedical literature
• DRKS — German clinical trials register

Market (4 sources)

• Crunchbase — funding rounds and M&A data
• SEC EDGAR — public company disclosures
• Grants.gov — SBIR/STTR and NIH awards
• Industry news feeds — press releases and announcements

Each source runs on its own crawl schedule — from daily for high-volume regulatory and clinical sources to weekly for patent databases and market feeds. The platform processes over 15,000 signals per day with an average detection latency of under 12 hours from source publication.

From Signal to Intelligence

Detection is only the first step. The real value of Signal Intelligence lies in the pipeline that transforms raw cross-domain signals into actionable business outcomes:

Competitive Monitoring

Track competitors across all four domains simultaneously. See when a competitor receives FDA clearance, files a patent in a new technology area, starts a clinical trial, or raises funding — and understand how these signals combine to reveal strategic direction.

Lead Generation

Identify companies with high signal density across regulatory, clinical, and market domains. A company that received recent regulatory approvals, has active clinical trials, and raised a Series A represents a validated, well-funded prospect ready for partnership or solution outreach.

Partner Scouting

Find CDMOs, contract manufacturers, and technology partners with the right regulatory footprint, patent portfolio, and clinical expertise. Cross-domain signal intelligence reveals capability depth that no single domain can provide.

Market Expansion Planning

Identify companies expanding into new geographic markets by monitoring regulatory activity across jurisdictions. Cross-reference with funding data to assess expansion readiness and with patent filings to understand technology positioning in each market.

Clinical Partnership Targeting

Monitor clinical trial activity to identify investigators, sites, and sponsors active in your therapeutic area. Combine with funding data to prioritize well-capitalized trials and with patent data to understand the competitive IP landscape.

Why Now?

The volume of publicly available signal data has exploded. Regulatory agencies worldwide publish more data than ever before. Clinical trial registries have expanded coverage and transparency requirements. Patent data is increasingly digitized and accessible. Funding data platforms provide real-time visibility into private company activity.

Yet most organizations still approach these domains in isolation — a regulatory affairs team monitors FDA while a business development team tracks funding rounds and an R&D team watches clinical trials. The opportunity lies in integration: cross-domain signal intelligence reveals patterns and connections that no single-domain approach can detect.

Companies that invest in cross-domain signal intelligence gain a structural advantage. They see market movements first, identify opportunities before competitors, make faster partnership decisions, and navigate regulatory complexity with the full context of competitive, clinical, and market dynamics.

Conclusion

Signal Intelligence represents a new category of business intelligence that cuts across traditional domain boundaries. By combining regulatory, competitive, clinical, and market signals from 24 global data sources, it provides the unified intelligence picture that complex, regulated industries need to compete effectively.

Whether you are monitoring competitors across multiple dimensions, generating qualified leads from cross-domain signal triggers, scouting partners with verified regulatory and clinical footprints, or planning market expansion with the full intelligence picture, the CI Platform delivers the signal intelligence you need — when you need it.